IL17A and psoriasis: During these years, biologics targeting tumor necrosis factor-alpha (TNF-α), interleukin (IL)−12/23 and IL−17 started to provide new and efficient treatment options as a second-step therapy for patients with moderate to severe psoriasis or for patients with contraindications for or no benefit from traditional systemic drugs [53].